On May 29, 2026, Haisco Pharmaceutical Group announced a licensing and research collaboration with Eli Lilly to develop innovative medicines across various therapeutic areas. Under the agreement, Haisco will lead the discovery of up to five target programs, while Lilly will handle clinical development and commercialization. Lilly gains exclusive rights to certain programs globally, whereas Haisco retains rights within specific territories. Haisco is set to receive up to $87 million in upfront payments and potentially $2.9 billion in further milestones and royalties. This partnership aims to enhance global development of new therapies, leveraging both companies’ strengths.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/sectors/healthcare/articles/haisco-announces-licensing-research-collaboration-095000306.html
